TrialLancet (London, England)2022

Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial.

Sinead Delany-Moretlwe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.